Pharma Stocks
-
Insider Buyers At aTyr Pharma Likely Disappointed With 19% Slide
The recent 19% drop in aTyr Pharma, Inc.’s (NASDAQ:ATYR) stock could come as a blow to insiders who purchased US$911.8k…
Read More » -
Why Eli Lilly Stock Climbed to a New All-Time High Today
Shares of Eli Lilly (LLY +1.56%) rose to a record high on Monday after the medicine maker announced positive clinical…
Read More » -
A Look At Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After Recent Share Price Cooling
Event context and recent stock move Indivior Pharmaceuticals (INDV) has been attracting attention after a mixed stretch in its share…
Read More » -
Assessing Ascendis Pharma (NasdaqGS:ASND) Valuation After Recent Share Price Weakness
Recent share performance and business snapshot Ascendis Pharma (NasdaqGS:ASND) stock has been under pressure recently, with the share price down…
Read More » -
Is First-in-Class FDA Approval For XOCOVA PEP Altering The Investment Case For Shionogi (TSE:4507)?
Shionogi announced that the U.S. FDA has approved XOCOVA (ensitrelvir) as the first oral antiviral for post-exposure prophylaxis of COVID-19…
Read More » -
Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech
© ipopba / iStock via Getty Images After years of lagging the market, healthcare may be taking on a new…
Read More » -
Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech
Quick Read Merck’s Keytruda posted $8 billion in Q1 sales, while Summit’s ivonescimab faces binary risk ahead of its November…
Read More » -
A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million
Andrew Reardon, CLO & Secretary at Ligand (LGND +0.46%), reported the sale of 5,000 shares of Common Stock for approximately…
Read More » -
Are Daiichi Sankyo Company’s (TSE:4568) ASCO 2026 ADC Data Deepening Its Oncology Moat?
In late May 2026, Daiichi Sankyo announced it would present more than 25 oncology abstracts at the ASCO 2026 meeting,…
Read More » -
Is Ligand Pharmaceuticals (LGND) Still Undervalued After Its Strong Recent Share Price Momentum
Recent performance context for Ligand Pharmaceuticals (LGND) Without a specific news event driving headlines today, Ligand Pharmaceuticals (LGND) still gives…
Read More »